437 related articles for article (PubMed ID: 30045635)
21. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions.
Hazafa A; Mumtaz M; Farooq MF; Bilal S; Chaudhry SN; Firdous M; Naeem H; Ullah MO; Yameen M; Mukhtiar MS; Zafar F
Life Sci; 2020 Dec; 263():118525. PubMed ID: 33031826
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment.
Liu B; Saber A; Haisma HJ
Drug Discov Today; 2019 Apr; 24(4):955-970. PubMed ID: 30849442
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
[TBL] [Abstract][Full Text] [Related]
24. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
[TBL] [Abstract][Full Text] [Related]
25. CRISPR-Cas9 as a Tool in Cancer Therapy.
Zatloukalová P; Krejčíř R; Valík D; Vojtěšek B
Klin Onkol; 2019; 32(Supplementum 3):13-18. PubMed ID: 31627701
[TBL] [Abstract][Full Text] [Related]
26. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
Li L; Hu S; Chen X
Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
[TBL] [Abstract][Full Text] [Related]
27. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
[TBL] [Abstract][Full Text] [Related]
28. Long Non-coding RNAs and CRISPR-Cas Edition in Tumorigenesis.
Furtado CLM; da Silva Santos R; Sales SLA; Teixeira LPR; Pessoa CDÓ
Adv Exp Med Biol; 2023; 1429():41-58. PubMed ID: 37486515
[TBL] [Abstract][Full Text] [Related]
29. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy.
Wang L; Zheng W; Liu S; Li B; Jiang X
Chembiochem; 2019 Mar; 20(5):634-643. PubMed ID: 30393919
[TBL] [Abstract][Full Text] [Related]
30. Long Noncoding RNA GMAN, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding GMAN-AS.
Zhuo W; Liu Y; Li S; Guo D; Sun Q; Jin J; Rao X; Li M; Sun M; Jiang M; Xu Y; Teng L; Jin Y; Si J; Liu W; Kang Y; Zhou T
Gastroenterology; 2019 Feb; 156(3):676-691.e11. PubMed ID: 30445010
[TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNAs in cancer: mechanisms of action and technological advancements.
Bartonicek N; Maag JL; Dinger ME
Mol Cancer; 2016 May; 15(1):43. PubMed ID: 27233618
[TBL] [Abstract][Full Text] [Related]
32. CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network.
Morelli E; Gulla' A; Amodio N; Taiana E; Neri A; Fulciniti M; Munshi NC
Methods Mol Biol; 2021; 2348():189-204. PubMed ID: 34160808
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas9-mediated deletion of lncRNA Gm26878 in the distant Foxf1 enhancer region.
Szafranski P; Karolak JA; Lanza D; Gajęcka M; Heaney J; Stankiewicz P
Mamm Genome; 2017 Aug; 28(7-8):275-282. PubMed ID: 28405742
[TBL] [Abstract][Full Text] [Related]
34. CRISPR/Cas9 small promoter deletion in H19 lncRNA is associated with altered cell morphology and proliferation.
da Silva Santos R; Pinheiro DP; Teixeira LPR; Sales SLA; Dos Santos Luciano MC; de Lima Melo MM; Pinheiro RF; Tavares KCS; Furtado GP; Pessoa C; Furtado CLM
Sci Rep; 2021 Sep; 11(1):18380. PubMed ID: 34526543
[TBL] [Abstract][Full Text] [Related]
35. Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.
Liu T; Shen JK; Li Z; Choy E; Hornicek FJ; Duan Z
Cancer Lett; 2016 Apr; 373(1):109-118. PubMed ID: 26806808
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9 for cancer research and therapy.
Zhan T; Rindtorff N; Betge J; Ebert MP; Boutros M
Semin Cancer Biol; 2019 Apr; 55():106-119. PubMed ID: 29673923
[TBL] [Abstract][Full Text] [Related]
37. State of the art technologies to explore long non-coding RNAs in cancer.
Salehi S; Taheri MN; Azarpira N; Zare A; Behzad-Behbahani A
J Cell Mol Med; 2017 Dec; 21(12):3120-3140. PubMed ID: 28631377
[TBL] [Abstract][Full Text] [Related]
38. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges.
Yi L; Li J
Biochim Biophys Acta; 2016 Dec; 1866(2):197-207. PubMed ID: 27641687
[TBL] [Abstract][Full Text] [Related]
39. [Application Progress of CRISPR/Cas9 System for Gene Editing in Tumor Research].
Liu C; Li Z; Zhang Y
Zhongguo Fei Ai Za Zhi; 2015 Sep; 18(9):571-9. PubMed ID: 26383982
[TBL] [Abstract][Full Text] [Related]
40. CRISPR/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis.
Hariprabu KNG; Sathya M; Vimalraj S
Int J Biol Macromol; 2021 Dec; 192():913-930. PubMed ID: 34655593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
